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Perbandingan Kesan Intravena Dexmedetomidine pada Cara Sasaran-Kawalan 
Infusi Propofol berbeza model (Marsh Vs Schneider) yang berbeza semasa Induksi 
Pembiusan 
 
ABSTRAK  
 
Latar belakang 
Dexmedetomidine adalah alpha-2 selektif agonis, yang sering digunakan sebagai ubat 
pelali dan menjadi ubat tambahan semasa pembiusan am. Tujuan kajian ini adalah untuk 
menentukan kesan dexmedetomidine semasa induksi menggunakan dua teknik 
farmakokinetik infusi kawalan sasaran (IKS) propofol. 
 
Tatacara 
64 pesakit yang berumur 18-60 tahun , dalam klasifikasi ASA I dan II yang menjalani 
pembedahan elektif secara pembiusan umum telah dibahagikan secara rawak kepada 
dua kumpulan ;Kumpulan Marsh(n=32) dan Kumpulan Schnider(n=32).Kesemua 
pesakit menerima ubat permulaan intravena dexmedetomidine pada 1 mcg/kg selama 10 
minit diikuti dengan IKS remifentanil 2ng/ml. Setelah kepekatan tempat sasaran (Ce) 
2ng/ml remifentanil tercapai, induksi IKS propofol dimulakan. Kumpulan Marsh 
dimulakan dengan model Marsh dengan tahap kepekatan (Cpt) 2mcg/ml, manakala 
kumpulan Schnider dimulakan dengan model Schnider menggunakan tahap kepekatan 
(Cet) 2mcg/ml. Sekiranya induksi tidak berjaya selepas 3 minit, tahap kepekatan (Ct) 
akan dinakkan 0.5mcg/ml setiap 30 saat sehingga induksi berjaya.Keperluan tahap 
kepekatan propofol semasa berjaya induksi, masa induksi dan propofol Ce semasa 
berjaya induksi dan parameter hemodinamik direkod untuk analisis statistik 
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Keputusan  
Keperluan propofol Ct untuk kejayaan induksi adalah rendah dengan signifikan di 
kumpulan Schnider berbanding kumpulan Marsh [3.48(0.90) vs 4.02(0.67)] g/ml; P = 
0.01]. Masa induksi pertengahan adalah lebih pendek di kumpulan Schnider berbanding 
kumpulan Marsh [134.96 (50.91) vs. 161.59 (39.64); P = 0.02] saat. Tidak terdapat 
perbezaan ketara antara Ce  dan parameter hemodinamik semasa kejayaan induksi di 
antara dua kumpulan. 
 
Kesimpulan  
Dexmedetomidine sebagai ubat induksi bersama dengan TCI remifentanil dan TCI 
propofol mengurangkan keperluan Ct untuk induksi dan mengurangkan masa induksi 
untuk model Schnider berbanding model Marsh bagi TCI propofol. Bagaimanapun, 
kesan hemodinamik adalah stabil dalam kedua-dua kumpulan. 
 
Kata-kata Kunci: Marsh,Schnider,propofol,dexmedetomidine, infusi kawalan sasaran 
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Comparison of the Effects of Intravenous Dexmedetomidine on Different Target-
controlled Infusion Pharmacokinetic Models of Propofol (Marsh vs. Schnider) 
during Induction of Anaesthesia 
 
ABSTRACT 
 
Background: Dexmedetomidine is selective alpha 2-agonist which is commonly used 
for sedation and potential to be used as co-induction drug. The aim of this study was to 
determine the effects of dexmedetomidine on induction using different target-controlled 
infusion (TCI) pharmacokinetic models of propofol. 
 
Methods: 64 patients, aged 18-60 year-old, classified under ASA I and II, who 
underwent elective surgery under general anaesthesia, were randomised into two 
groups; Group Marsh (n=32) and Group Schnider (n=32). All patients received 1 
mcg/kg loading dose of intravenous (IV) dexmedetomidine over 10 minutes and 
followed with TCI remifentanil at 2 ng /ml. After effect-site concentration (Ce) of 
remifentanil achieved 2 ng/ml, TCI propofol induction was started. Group Marsh was 
started with Marsh model at target plasma concentration (Cpt) of 2 mcg/ml, whereas 
Schnider group was started with Schnider model at target effect concentration (Cet) of 2 
mcg/ml. If induction was unsuccessful after 3 min, target concentration (Ct) was 
gradually increased to 0.5 mcg/ ml every 30 seconds until succesful induction. Ct 
requirement of propofol at successful induction, induction time, Ce of propofol at 
successful induction and serial of haemodynamic parameters were recorded for 
statistical analysis. 
 
x 
 
Results: Requirement of Ct of propofol for successful induction was significantly lower 
in Group Schnider than Group Marsh [3.48 (0.90) vs. 4.02 (0.67) g/ml; P = 0.01]. 
Mean induction time was also shorter in Group Schnider than Group Marsh [134.96 
(50.91) vs. 161.59 (39.64); P = 0.02] seconds. There were no significant differences in 
Ce at successful induction and haemodynamic parameters between the two groups.  
 
Conclusions: Dexmedetomidine as co-induction with TCI remifentanil and TCI 
propofol reduced Ct requirement for induction and shorter induction time in Schnider 
model than Marsh model of TCI propofol. However, haemodynamic effects were stable 
in both groups.  
 
Keywords: Marsh model, Schnider model, propofol, dexmedetomidine, target-
controlled infusion, induction time, target plasma concentration, target effect 
concentration.  
 
 
 
1 
 
SECTION 1 
INTRODUCTION 
 
1.0 Introduction 
Dexmedetomidine is a highly selective alpha-2-adrenoreceptor agonist which has 
properties of sedation, hypnosis and analgesia (1). It has been used as conscious 
sedation in intensive care unit (ICU), during procedural sedation, and as an adjunct drug 
for regional anaesthesia as well as peripheral nerve block . Dexmedetomidine provide 
sedation and analgesia without respiratory depressant (2). 
 
 
 
 
Figure 1 Molecular structure of dexmedetomidine (source: precedex full 
prescribing information, Hospira) 
 
Dexmedetomidine is administered in adults with dosing of 1 micrograms/kg 
followed by 0.2-0.7 micrograms/kg/hour (3). Dexmedetomidine is 94% protein-bound 
in the plasma, distribution half-life is 6 minutes and undergoes extensive hepatic 
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metabolism to methyl and glucuronide conjugates (3). Dexmedetomidine elimination 
half life is 2 hours and 95% of metabolites are excreted in the urine (3). 
 
Remifentanil is a selective mu opioid agonist(4). Remifentanil has a unique 
structure due to its ester linkage which is hydrolysed by nonspecific plasma and tissue 
esterases to inactive metabolites(4). Thus, remifentanil effect are fast, rapidly titratable 
due to its fast onset and offset, non cumulative and fast recovery after discontinuation 
(4). 
 
Figure 2 Molecular structure of Remifentanil (source: remifentanil prescribing 
info, Mylan) 
 
With the availability of sophisticated drug delivery system such as target 
controlled infusion (TCI), Remifentanil can be delivered by precise titration to achieve 
narrow therapeutic margin (5). TCI Remifentanil can be delivered via Minto mode(6). 
 
Propofol is a phenol derivative with chemical name 2,6-diisopropylphenol (3). 
Propofol is presumed to act on GABA-A receptor to produce anaesthesia effect (4). In 
healthy adults, the induction dose is 1.5-2.5mg/kg intravenous, with corresponding 
blood levels of 2-6 micrograms/ml to produce loss of consciousness (4). 
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The usage of Dexmedetomidine was further extended as adjunct in general 
anaesthesia which includes being used as adjunct in total intravenous anaesthesia 
(TIVA) and was shown to have several added advantages. During intracranial 
procedure, Dexmedetomidine as an anaesthetic adjunct leads to better perioperative 
hemodynamic control, less intraoperative opiod consumption, and fewer postoperative 
antiemetic requests (7). Dexmedetomidine as adjunct to Propofol and Remifentanil 
based anaesthesia reduced the total Propofol dose requirement and produce a more 
stable intraoperative haemodynamics (8). Intraoperative infusion of Dexmedetomidine 
leads to smooth and haemodynamically stable emergence (9). 
 
Compared to inhalational technique, TIVA has less post operative nausea and 
vomiting, less usage of antiemetic, produce less headache and less drowsiness (10). 
TIVA can be used in any type of surgery unless contraindicated (6). TIVA can be 
delivered via a sophisticated system called TCI where Propofol and Remifentanil can be 
delivered via such methods using specific pharmacokinetic mode (6).TCI Propofol can 
be delivered via Marsh or Schnider mode. According to Malaysia TIVA/TCI pocket 
reference (2nd edition), recommended initial target concentration for TCI Propofol is 
4mcg/ml and for TCI Remifentanil is 2ng/ml (6). However, when BIS monitoring is 
used, a lower initial target concentration of TCI propofol at 2mcg/ml is used (6). 
 
Early TCI machine was designed to produce target plasma concentration. Soon 
after that, it was noted that there is a delay between plasma concentration and clinical 
effect which is due to the time taken for equilibrium between plasma concentration and 
the site of action at central nervous system, known as effect-site (12). The rates of 
plasma/effect site equilibriums are determined by factors such as cardiac output, 
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cerebral blood flow and lipid solubility of the drug (13). Mathematically, this time 
course for plasma/effect site equilibration was described by a first order kinetic known 
as Keo (13). To achieve the effect-site targeting, the TCI machine will manipulate 
plama concentration to achieve the effect-site concentration by overshooting the plasma 
concentration or stopping the infusion (13). The degree of overshooting the plasma 
concentration or stopping the infusion will depend on the Keo and rate of plasma 
redistribution (13).Keo(min/1) for Marsh model is 0.26, modified Marsh is 1.21 and 
Schnider is 0.456. The time to peak effect for Marsh is 4.5minutes, for modified Marsh 
is 1.5 minutes and Schnider is 1.5minutes (12). 
 
Marsh and Schnider model with different pharmacokinetic parameter when used 
can result in significantly different in infusion rate. This different in infusion rate will 
result in different pharmacodynamics response during anaesthesia. Previous study 
examined the effect of intravenous Dexmedetomidine on TCI Propofol in a single 
mode. The purpose of this study is to compare the effect of intravenous 
Dexmedetomidine on two different TCI mode of Propofol (Marsh vs Schnider) on 
haemodynamic changes, induction time and effect-site concentration of TCI Propofol. 
This study is important because haemodynamic stability and smoothness of induction is 
an important aspect to be achieved during induction of anaesthesia. 
 
Few studies had been done to examine Dexmedetomidine as an anaesthetic 
adjunct which can provide some insight to lead our research further on this aspect. Ke 
Peng et al. studied the efficacy and safety of Dex as an anaesthetic adjunct for patients 
undergoing intracranial surgery (7). It was a meta-analysis study where systemic 
literature search of randomized controlled trials was done to compare Dex with placebo 
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or opioids in these patients. Eight RCT were included in the study. The study showed 
that patients treated with Dexmedetomidine required less intraoperative treatment for 
hypertension and hypotension (RR= 0.48, 95% CI 0.31-0.75, p=0.001; and RR=0.66, 
95% CI 0.43-1.01, p=0.05, respectively) and less postoperative treatment for 
hypertension and tachycardia ( RR=0.37, 95% CI 0.17-0.79, P=0.01; and RR=0.14, 
95% CI 0.03-0.59, p=0.007, respectively) compared with placebo. Patients also had 
lower mean arterial pressure and heart rate when extubated (MD=-9.7mmHg, 95% CI -
12.35 to -7.12, p<0.00001; and MD= -16.35 beats/minute, 95% CI -20.00 to -12.70, 
p<0.00001, respectively), a lower intraoperative additional fentanyl consumption 
(MD=-0.78mcg/kg/min, 95% CI -1.51 to -0.05, p=0.04), and a lower postoperative 
antiemetic requests ( RR=0.51, 95% CI 0.33-0.80, P=0.003). 
 
Kang W S et al. studied the effect of dexmedetomidine on the adjuvant propofol 
requirement and intraoperative hemodynamics during remifentanil-based anaesthesia in 
twenty patients undergoing breast surgery (8). Patients were randomly allocated to 
receive dexmedetomidine (group dex) or placebo (group c). It was concluded that group 
dex require lesser propofol infusion rate than group c (63.9 +/-16.2 vs 96.4 +/- 
10mcg/kg/min, respectively p<0.001) and also produce a more stable intraoperative 
hemodynamics). 
 
Viterbo J F et al. compared Marsh and Schnider model during induction of 
anaesthesia in elective cardiac surgery (11). It was shown that marsh model produce 
lower predicted effect-site concentration (2.3+/-0.4 vs 2.7 +/-0.6mcg/ml, p=0.006) and a 
shorter time to induction (296+/-59 vs 338+/-87s, p=0.024). 
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Naaz S et al. stated that frequently observed adverse effects with dex use include 
hypotension, hypertension, bradycardia, dry mouth and nausea (14). Other reported 
adverse effects include fever, rigors, cyanosis, muscle weakness. It may also lead to 
arrhythmia, AV block, cardiac arrest, T-wave inversion, tachycardia, angina pectoris, 
pulmonary edema, bronchospasm, respiratory depression, syncope, neuropathy, 
paresthesia, paresis, hyperkalemia, lactic acidosis and hyperglycemia. In healthy 
subjects, tolerability of dex was noted in subjects who achieved plasma concentrations 
from 1.8 up to 13 times the upper boundary of therapeutic range. Dex when 
coadminister with other anaesthetics, sedatives, hypnotics or opiods will lead to 
enhancement of it effects, thus a reduce dosage with these agents is required. 
 
Ghodki PS et al. study the effect of dex as an anaesthetic adjuvant in 
laparascopic surgery (15). 30 patients were loaded with dex at 1mcg/kg followed by 
routine induction with propofol and fentanyl. There is a statistically significant 
reduction in heart rate, however is not clinically significant. The mean heart rate on 
starting was 85(17) reduce to lowest mean of 72(13). Mean systolic blood pressure was 
125(22) at beginning fell to 113(20). Mean diastolic blood pressure fell at statistically 
insignificant value, 68(12) to 56(10). From this literature, using dexmedetomidine with 
propofol together will lead to risk of reduction in blood pressure and heart rate, 
however, this risk is tolerable to the patient. 
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1.1 Rationale of Study 
This study was to to compare the effect of IV dexmedetomidine on different TCI mode 
of propofol (Marsh vs Schnider) on haemodynamic changes, induction time and effect-
site concentration of TCI propofol during general anaesthesia. Previous study which 
was done by Viterbo J F et al. compared this two TCI propofol mode without IV 
dexmedetomidine preloading. This research is necessary because haemodynamic 
stability and smoothness of induction is an important aspect to be achieved during 
induction of anaesthesia. Thus the aim of this study is to determine the clinical effect of 
IV dexmedetomidine between two different TCI propofol modes. 
 
1.2 Objective of the Study 
Primary objective: 
 To compare the effect of intravenous Dex on the hemodynamic changes 
(decrease in mean blood pressure) during induction and after endotracheal 
intubation between marsh and schnider models of TCI propofol 
Secondary objective: 
 To compare the effect of intravenous Dex on induction time between Marsh and 
Schnider models of TCI propofol 
 To compare the effect of intravenous Dex on the effect site concentration of 
propofol at successful induction between Marsh and Schnider models of TCI 
propofol 
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SECTION 2 
STUDY PROTOCOL 
 
2.1 Study Protocol 
Study design : prospective, randomized control trial, double-blinded 
Study period : 1/6/2015-1/6/2016 
Study population :  patient in Hospital University Sains Malysia(HUSM) undergone 
elective surgery, requiring general anaesthesia, requiring 
intubation. The tracheal tube used for endotracheal intubation 
was the standard polyvinylchloride (PVC) type. 
Study setting  : Operation theatre (OT), HUSM 
Sample Recruitment Criteria: 
a) Inclusion criteria : 
 Patients with age 18-60 
 ASA 1-2 
 
b) Exclusion criteria: 
 Any allergic to study drugs 
 Preoperative bradycardia, heart rate (HR) <55/minute or cardiac 
dysrhytmia 
 Preoperative hypotension  mean arterial pressure(MAP) <60mmhg 
 Known difficult intubation  
 Pregnancy 
 Liver or renal disease 
 Obesity 
 Hypertension  
 
c) Withdrawal criteria: 
 Unanticipated difficult intubation ( requiring more than 30 sec for 
intubation , or more than 1 attempt for intubation) 
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 Severe hypotension or bradycardia after starting infusion of study drug 
requiring rescue drugs (ephedrine/atropine) that was given up to the time 
of 5 minutes post intubation. 
 
Methodology: 
 Obtained approval from ethics committee HUSM and Medical Research & 
Ethics Comittee. 
 Patients scheduled for elective surgery was seen two or more days earlier and 
selection of patient based on criteria. 
 Written consent was obtained from the patient. 
 No sedative premedication was given. 
 Study numbers ranged from 01 to 80 were prepared. These numbers would 
either be labelled as group M (marsh) or group S (schnider). This randomization 
was done through internet, at the website of www.randomization.com. 80 
subjects were randomised into 20 blocks. Thus, those study numbers would be 
divided into 2 groups equally, group M (marsh) and group S (schnider). 
 This was a double blinded study. The person (MO in charge) who assessed the 
patient in the OT and the patients would not know which mode of TCI propofol 
was used. 
 Non invasive monitoring such as pulse oximetry, electrocardiogram (ECG) 
,bispectral index (BIS) and non invasive blood pressure (NIBP) were attached to 
patient once admitted to OT. 
 Two 18G IV branulla was setted to the patient. Both were attached to a three 
way stopcock.One was dedicated for infusion of TCI propofol and remifentanil.  
 The second IV access was dedicated for infusion of ringer lactate and dex 
 IV ringer lactate 10ml/kg preloading was infused to the patient 
 This was followed by IV Dex 1mcg/kg was infused over 10 minutes. The dosing 
was based on Precedex full prescribing information, last revised September 
2014, downloaded from internet at http://www.precedex.com/wp-
content/uploads/Precedex_PI.PDF. 
 TCI remifentanil was started at 2ng/ml, using Minto model. 
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 Once the target concentration of remifentanil was achieved (which will be 
shown in the display monitor of the TCI machine), TCI propofol was started at 
2mcg/ml, which was either using Marsh or Schnider model, based on 
randomisation. 
 When using Marsh model, plasma concentration mode was used. When using 
Schnider model, effect-site concentration mode was used. 
 Successful of induction is monitored via loss of verbal response and BIS score 
<55. If after 1 minutes and successful of induction is not achieved, propofol is 
titrated up by 0.5mcg/ml every 30 sec until loss of verbal response and BIS 
score<55 is achieved. 
 Effect site concentration and BIS value were recorded at the time of successful 
induction. Effect site concentration was obtained from the display monitor of 
TCI machine. 
 Once successful induction, rocuronium 0.6mg/kg is given followed by tracheal 
intubation 3 minutes later. 
 Intravenous ephedrine 6mg will be given whenever MAP<60mmhg and 
intravenous atropine 0.5mg will be given when HR<50/minutes. The dose of 
atropine is based on Bradycardia ACLS algorithm. Patients who were 
administered atropine or ephedrine within the time frame of starting iv dex 
infusion up to the time of 5 minutes post intubation were excluded from the 
study. 
 Patients with unanticipated difficult intubation and develop severe hypotension 
and bradycardia requiring rescue drugs (atropine/ephedrine) after infusion of 
study drugs will be withdrawn. This patients will be observed for two hours in 
recovery bay and will only be discharged to ward once all the haemodynamic 
parameters are stable. The withdrawn patients will not be replaced. 
 The following data will be recorded: 
-induction time taken (secondary end points) 
-blood pressure and heart rate during induction of anaesthesia at four time 
interval (T-baseline, T-after loading, T-after TCI remifentanil and T-after 
successful TCI propofol induction) (primary end points). 
-effect site concentration of TCI-propofol after successful induction of TCI 
propofol (secondary end points). 
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-blood pressure and heart rate after endotracheal intubation at three time interval     
(T-before intubation, T-1 min after intubation, T-5 min after intubation) between 
two groups (primary end points) 
-BIS score at five time interval ( T-baseline, T-after loading, T-after TCI 
remifentanil ,T-after successful TCI propofol induction, and T-5min after 
intubation) 
 Dex infusion will be given loading dose at 1mcg/kg over 10 minutes, assuming 
the maximum weight of patient enrol in this study is 100kg, he will require 
100mcg of Dex. Each vial of Dex contain 200mcg of dex in 2ml solution. 2 ml 
Dex will be diluted with 48ml 0.9% sodium chloride to achieve concentration of 
4mcg/ml.The required amount will be calculated and the exact amount will be 
drawn up for him. The total dose of propofol and remifentanil will depend on 
patient parameters (gender, age, weight, and height), haemodynamic responses 
and the length of surgery. Infusion of propofol and remifentanil is done through 
individual TCI machine using 50ml syringes, which will alert the user when to 
volume of the infuse drug is reaching the end. By this time the infused drugs 
will be topped up manually. The combination medication will cover the required 
period.  
 
Sample size calculation: 
 The sample size calculation is based on the study by Viterbo J F et al (2012) for 
all the three objective in this study .We use power and sample size calculations 
software version 3.1.2 using independent t-test. For the first objective, sample 
size was estimated to detect a 10% difference between groups in decrease in 
mean blood pressure, with a power of 0.8 and α=0.05. Calculated sample size is 
28 per group. 
 For the second objective, sample size was estimated based on mean difference of 
14% between group in time to induction, with a power of 0.8 and α=0.05. 
Calculated sample size is 32 per group. 
 For the third objective, sample size was estimated based on mean difference of 
17% between group in predicted effect-site concentration, with a power of 0.8 
and α=0.05. Calculated sample size is 17 per group. 
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 The highest sample size calculated was based on the second objective, different 
in group in induction time. Calculated sample size is 64. Taking into account at 
20% sample drop out rate, the total number of patient required will be 80. 
 
Statistical analysis: 
Objective parameter Statistical analysis 
 To compare induction time between two groups Independent t-test 
 To compare haemodynamic changes (MAP and HR) 
during induction of anaesthesia at four time interval ( 
T-baseline, T-after dexmedetomidine loading, T-after 
TCI remifentanil, T-after successful propofol 
induction)  
Repeated measures 
ANOVA and paired t-test 
 To compare haemodynamic changes (MAP and HR) 
after endotracheal intubation at three time intervals ( 
T-before intubation, T-1 min after intubation, T-5 
min after intubation) between two groups  
Repeated measures 
ANOVA and paired t-test 
 To compare effect site concentration of propofol at 
successful induction 
Independent t-test 
 
Concurrent medications: 
The following medications are not permitted during their study: 
 Any sedative premedication (eg:midazolam, morphine) 
 
The following medications are permitted during their study: 
 Steroids (eg:dexamethasone, hydrocortisone) 
 Non steroidal anti-inflammatory drugs (eg: brufen, celecoxib, paracetamol) 
 Antibiotics ( eg: cefuroxime, augmentin, metronidazole, ceftriaxone) 
 Antiepileptics ( eg: gabapentin, carbamazepine) 
 Antiyhroids (eg ; carbimazole, prophylthiouracil ) 
 Tramadol  
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Flow chart of Study 
Approval from ethics committee HUSM and NMRR. 
↓ 
Selection of patients based on criteria being determined. 
↓ 
Obtain written consent from patients. 
↓ 
Premedication is omitted from the patient. 2 dedicated intravenous access is applied, 
one for TCI propofol and TCI remifentanil infusion. The other for intravenous Dex and 
ringer’s lactate. 
↓ 
Standard monitoring of baseline saturation, ECG ,blood pressure and BIS is applied.  
↓ 
IV ringer’s lactate 10ml/kg preloading is given 
↓ 
Patient is randomized into two groups, marsh (M) and schnider (S) 
↓ 
Marsh (M) group 
(n=40) 
Schnider (S) group 
(n=40) 
 Iv Dex 1mcg/kg over 10 minutes 
 TCI remifentanil using Minto model 
with target concentration of 2ng/ml 
 TCI propofol using Marsh model with 
target concentration of 2mcg/ml, 
titrating upward to loss of verbal 
response and BIS<55 
 Iv Dex 1mcg/kg over 10 minutes 
 TCI remifentanil using Minto model 
with target concentration of 2ng/ml 
 TCI propofol using Schnider model 
with target concentration of 2mcg/ml, 
titrating upward to loss of verbal 
response and BIS<55 
↓ 
IV rocuronium 0.6mg/kg followed by intubation after 3 minutes 
↓ 
Following data will be recorded 
↓ 
 Induction time taken for successful induction 
 Haemodynamic changes (MAP and heart rate) at four time interval (T-baseline, T-
after Dex loading, T-after TCI remifentanil, T-after successful propofol induction) 
 Effect site concentration of TCI-propofol after successful induction 
 Haemodynamic changes (MAP and heart rate) at three time interval ( T-before 
intubation, T-1 min after intubation, T-5 min after intubation) 
 BIS score at five time interval (T-baseline, T-after Dex loading, T-after TCI 
remifentanil, T-after successful propofol induction and T-5 mins after intubation 
↓ 
Maintenance of subsequent anaesthesia according to respective TCI model 
↓ 
Data collection 
↓ 
Statistical analysis 
↓ 
Dissertation report writing 
↓ 
Submission of dissertation 
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While the study is In proa,ress. we request you to submit to us the folk)wlna document~ 
1. Application for ttnewJI of ethlcel approval 60 days before tht e•plt~tlon dote of this 
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Application Form. Subsequently this need to be done vtatly as long as the research goes on. 
2. Any Changes in the protocol. tspedally.those that may adversely affe-c:t the u fety of the 
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Procedures (SOPs), and Local Regulations and Standards in Ethical Review. 
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Member Occupation Male/ Tick (.I) If Female present when (Title and Name) (Designation) (M/F) above item5, 
were reviewed 
Deputy Chairperson : 
Professor Or. Mohd Shukri Othman Deputy Chairperson of Jawatankuasa M v' 
Etika Penyelidikan (Manusiaj, JEPeM (Deputy 
V$M Chairperson) 
Secretariat: 
Miss Siti htihah Ariffin ReseiHC-h Offiter F ,I 
Members: 
1. Professor Dr. Zeehalda Lecturer. School of Medical Sciences F v' 
Mohamed 
2. Associate Professor Or. l ee Lectu rer, School o f Medical Sc:iences M v' 
Yeono Yeh 
3. Or. Teguh Harvo Sasongko Lecturer; Human Genome Center M v' 
4. Or. Azlan Husin Lecturer, Sdlool of Medical Sciences M v' 
s. or. Haslina Taib Lecturer, SChool of Dental Sciences F ,I 
6. Mrs. Zawiah Abu Sakar Community Representative F ,I 
Jawatankuasa Etik.a Penyelidikan (Manusia), JEPeM·USM is in compliance w ith the Declaration of Helsinki, 
International Conference on Harmonizat ion (ICH) Guidelines, Good Clinical Practice (GCP} Standards, Council 
for International Organllations of Medical Sdences (C.IOMS) Guidelines, World Health Organization (WHO) 
Standards and Operationetl Guidance for Ethics fteview of Health4 Related Research and Surveying and 
Evaluati ng Ethical Review Practices, £C/IRB Standard Operating Procedure-s (SOPS}; and Local Regulatlon.s 
and Stand rds in Ethital Review. 
~ 
PROFESSOR OR._!!19HEYSHUKRI OTHMAN 
Deputy Chairperson 
Jawatankuasa Etika Penyelidikan (Manusia), JEPeM 
Univers.iti Sains Malaysia 
18 
 
SECTION 3 
BODY CONTENT 
3.1 Title page 
Title:  
Comparison of the Effect of Intravenous Dexmedetomidine on Different Target-
controlled Infusion Pharmackinetic Models for Propofol (Marsh vs. Schnider) 
during Induction of Anaesthesia 
 
Short title:  
The Effects of Dexmedetomidine on Marsh and Schnider Models of Target-controlled 
Infusion Propofol 
 
Authors’ names and institutional affliation: 
1. Hai Siang TAN 
Department of Anaesthesiology, School of Medical Sciences, Jalan Sultanah 
Zainab II, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan 
 
2. Wan Mohd Nazaruddin WAN HASSAN 
Department of Anaesthesiology, School of Medical Sciences, Jalan Sultanah 
Zainab II, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan 
 
 
 
 
 
19 
 
Corresponding author: 
Tan Hai Siang, MD 
Department of Anaesthesiology, School of Medical Sciences, Jalan Sultanah Zainab II, 
Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan. 
Tel no: +60128039500 
Fax no: +6097653000 
Email: haisiang@hotmail.com 
 
Conflict of interest: None 
 
Acknowledgement:  
I would like to acknowledge Wong Weng Kin for his help on statistical analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
3.2 Main document 
Title: 
Comparison of the Effects of Intravenous Dexmedetomidine on Different Target-
controlled Infusion Pharmacokinetic Models of Propofol (Marsh vs. Schnider) 
during Induction of Anaesthesia 
Abstract 
Background: Dexmedetomidine is selective alpha 2-agonist which is commonly used 
for sedation and potential to be used as co-induction drug. The aim of this study was to 
determine the effects of dexmedetomidine on induction using different target-controlled 
infusion (TCI) pharmacokinetic models of propofol. 
 
Methods: 64 patients, aged 18-60 year-old, classified under ASA I and II, who 
underwent elective surgery under general anaesthesia, were randomised into two 
groups; Group Marsh (n=32) and Group Schnider (n=32). All patients received 1 
mcg/kg loading dose of intravenous (IV) dexmedetomidine over 10 minutes and 
followed with TCI remifentanil at 2 ng /ml. After effect-site concentration (Ce) of 
remifentanil achieved 2 ng/ml, TCI propofol induction was started. Group Marsh was 
started with Marsh model at target plasma concentration (Cpt) of 2 mcg/ml, whereas 
Schnider group was started with Schnider model at target effect concentration (Cet) of 2 
mcg/ml. If induction was unsuccessful after 3 min, target concentration (Ct) was 
gradually increased to 0.5 mcg/ ml every 30 seconds until succesful induction. Ct 
requirement of propofol at successful induction, induction time, Ce of propofol at 
successful induction and serial of haemodynamic parameters were recorded for 
statistical analysis. 
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Results: Requirement of Ct of propofol for successful induction was significantly lower 
in Group Schnider than Group Marsh [3.48 (0.90) vs. 4.02 (0.67) g/ml; P = 0.01]. 
Mean induction time was also shorter in Group Schnider than Group Marsh [134.96 
(50.91) vs. 161.59 (39.64); P = 0.02] seconds. There were no significant differences in 
Ce at successful induction and haemodynamic parameters between the two groups.  
 
Conclusions: Dexmedetomidine as co-induction with TCI remifentanil and TCI 
propofol reduced Ct requirement for induction and shorter induction time in Schnider 
model than Marsh model of TCI propofol. However, haemodynamic effects were stable 
in both groups.  
 
Keywords: Marsh model, Schnider model, propofol, dexmedetomidine, target-
controlled infusion, induction time, target plasma concentration, target effect 
concentration.  
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Introduction 
Dexmedetomidine is highly selective alpha-2-adrenoreceptor agonists which possess 
sedative, hypnotive and some analgesic effects. (1) It is commonly used for conscious 
sedation in intensive care unit (ICU) and monitored anaesthesia care procedures, and 
also as an adjunct drug for regional anaesthesia as well as peripheral nerve block. If it is 
compared to other sedative agents, one of the advantage of dexmedetomidine is its 
ability to provide more conscious sedation without respiratory depression effect and at 
the same time is able to provide some analgesic effect (2). 
 
The usage of dexmedetomidine is currently further extended to an adjuvant drug 
during general anaesthesia which include being used for pre-medication, co-induction 
and adjuvant in total intravenous anaesthesia (TIVA) technique. It has been shown to 
provide better perioperative haemodynamic control, less intraoperative opioid 
consumption, and fewer postoperative antiemetic requests during intracranial procedure 
(3). Its effect as as adjuvant to propofol and remifentanil based anaesthesia also has 
been shown to reduce total propofol dose requirement and produced more stable 
intraoperative haemodynamics (4). The emergence from anaesthesia was also smooth 
and stable haemodynamically with intraoperative infusion of dexmedetomidine (5).  
 
TIVA is a technique of anesthesia that conventionally using all intravenous 
drugs without using inhalational agents. This technique has less post operative nausea 
and vomiting, less usage of antiemetic, produce less headache and less drowsiness than 
inhalational anaesthesia technique (6). TIVA can be provided either using mannually-
controlled infusion technique or more advanced technique, which is target-controlled 
infusion (TCI) technique. TCI is a method of administrating certain intravenous drugs 
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based on setting of target plasma or target effect-site (brain) concentration using special 
infusion pump, which is incorporated with software of algorithm of pharmacokinetic 
parameters of that drugs. Two drugs that are currently capable to be administered using 
TCI are propofol and remifentanil. There are only two validated pharmacokinetic 
models of propofol available for clinical usage in adult, which are Marsh and Schnider 
models whereas only Minto model is available for TCI remifentanil.  
 
Marsh and Schnider model are derived from different pharmacokinetic 
parameters from different population pharmacokinetic, which can result in significantly 
different in infusion rate on adminitration. This different in infusion rate might result in 
different pharmacodynamics response during anaesthesia. The Marsh model was the 
first model developed for TCI propofol that commonly used target plasma concentration 
(Cpt) mode by taking into account of the patient’s weight and age. On the other hand, 
Schnider model is a newer developed model that commonly used target effect-site 
concentration (Cet) mode by taking into account of patient’s weight, height, age and 
gender  to derive the lean body mass (7). There is also Marsh model with effect site 
concentration mode in some TCI pumps and were also being called as modified Marsh 
model (8). 
 
The aim of this study was to compare the effects of loading intravenous (IV) 
dexmedetomidine co-induction on target concentration requirement for succesful 
induction, induction time, effect-site concentration at successful induction and 
haemodynamic changes between TCI propofol induction using Marsh and Schnider 
models.  
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Materials and Methods 
This was a prospective, double-blinded, randomised controlled trial, conducted in the 
university hospital (Hospital Universiti Sains Malaysia). 
 
After approval from university ethics committee and written inform consent 
from all patients, 62 patients undergoing elective surgery under general anaesthesia, 
with aged between 18-60 year-old and American Society of Anaesthesiologists (ASA) 
class I-II, were randomized into two groups; Group Marsh (n=32) and Group Schnider 
(n=32). Those patients with history of allergies to study drugs, preoperative bradycardia 
with heart rate (HR) < 55 beats/minute, cardiac dysrhythmia, preoperative hypotension 
with mean arterial pressure (MAP) <60 mmHg, known history of difficult intubation, 
pregnancy, liver or renal disease, obesity and hypertension were excluded from the 
study. Patients were withdrawn from study in the event of unanticipated difficult 
intubation, severe hypotension or bradycardia after starting infusion of study drugs that 
required optimisation with rescue drugs (atropine/ ephedrine). 
 
Randomisation 
A study number of 01 to 80 was prepared. These numbers was labelled as Group M 
(Marsh) or Group S (Schnider) and the randomization was done through internet, at the 
website of www.randomization.com. 80 subjects were randomised into 20 blocks and 
these study numbers were divided into 2 groups equally, Group M (Marsh) and Group S 
(Schnider). The study was completed after 64 patients successfully recruited. Initial 80 
subjects for randomisation were based on calculation of 20 % drop out rate. 
 
 
